Asset Details
Do you wish to reserve the book?
Targeting iron metabolism in drug discovery and delivery
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting iron metabolism in drug discovery and delivery
Do you wish to request the book?
Targeting iron metabolism in drug discovery and delivery
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting iron metabolism in drug discovery and delivery
2017
Overview
Key Points
Iron metabolism is a tightly regulated physiological process that has relatively low redundancy, and its deregulation often leads to iron deficiency or iron overload.
Iron deficiency and iron overload are historically associated with erythroid disorders; however, deregulated iron metabolism is also implicated in numerous ageing-related, non-haematological disorders, including neurodegenerative disorders, atherosclerosis and cancer.
Intracellular iron is directly involved in the formation of reactive oxygen species, which can cause cellular oxidative damage. Reactive oxygen species are also important for ferroptosis, a form of non-apoptotic cell death.
The internalization of iron by macrophages can modulate macrophage activity towards a pro-inflammatory phenotype, which may also depend on the pathway of iron intake.
Agents that interfere with key regulators of iron metabolism and cellular iron trafficking represent a promising new class of therapeutic agents for various diseases because these agents exploit pathological pathways that are complementary to those targeted by existing treatments.
Targeting therapeutics to diseased tissues that express high levels of transferrin receptor is a strategy that is used by several agents currently in clinical development, and extending this strategy towards other iron metabolism-associated cellular transporters may be advantageous.
Dysregulation of iron homeostasis occurs in haematological disorders and in other diseases such as cancer and neurodegeneration. Crielaard and colleagues discuss the progress made in interfering with iron metabolism as a therapeutic strategy, as well as in using iron metabolism to direct drugs to target tissues.
Iron fulfils a central role in many essential biochemical processes in human physiology; thus, proper processing of iron is crucial. Although iron metabolism is subject to relatively strict physiological control, numerous disorders, such as cancer and neurodegenerative diseases, have recently been linked to deregulated iron homeostasis. Consequently, iron metabolism constitutes a promising and largely unexploited therapeutic target for the development of new pharmacological treatments for these diseases. Several iron metabolism-targeted therapies are already under clinical evaluation for haematological disorders, and these and newly developed therapeutic agents are likely to have substantial benefit in the clinical management of iron metabolism-associated diseases, for which few efficacious treatments are currently available.
Publisher
Nature Publishing Group UK,Nature Publishing Group
